Please use this identifier to cite or link to this item:
|Title:||The impact of health-policy-driven subsidisation of prostate magnetic resonance imaging on transperineal prostate biopsy practice and outcomes.||Austin Authors:||Wei, Gavin ;Reeves, Fairleigh;Perera, Marlon ;Kelly, Brian D ;Esler, Stephen J ;Bolton, Damien M ;Jack, Gregory S||Affiliation:||Radiology
Surgery (University of Melbourne)
Olivia Newton-John Cancer Wellness and Research Centre
Department of Urology Memorial Sloan Kettering Cancer Center New York New York USA..
|Issue Date:||11-Feb-2022||Date:||2022-07||Publication information:||BJUI compass 2022; 3(4): 304-309||Abstract:||From 1 July 2018, the Australian Medicare Benefits Schedule (MBS) introduced rebates for multi-parametric magnetic resonance imaging (mpMRI) for the workup for prostate cancer (PCa). We aimed to determine if subsidisation of mpMRI prior to transperineal biopsy altered our institution's prostate biopsy practice patterns and outcomes. All patients who underwent transperineal prostate biopsy at an Australian tertiary institution from 1 January 2017 to 1 January 2020 were identified. Patients with known PCa were excluded. Patients were stratified into two groups: a pre-subsidisation cohort comprising patients biopsied prior to the introduction of mpMRI subsidisation on 1 July 2018 and a post-subsidisation cohort comprising patients biopsied after 1 July 2018. Histopathological results were compared with further stratification based on mpMRI results. Clinically significant cancer was defined as ISUP Grade Group ≥ 2. Six hundred and fifty men fulfilled the inclusion criteria. Three hundred and sixty-one patients were in the pre-subsidisation cohort and 289 in the post-subsidisation cohort. Of the patients in the pre-subsidisation group, 36.3% underwent a pre-biopsy mpMRI compared with 77.5% in the post-subsidisation group. Of the patients in the pre-subsidisation group, 59.6% had positive biopsies (p = 0.024) compared with 68.2% in the post-subsidisation group. The rate of clinically significant PCa was lower in the pre-subsidisation group (39.1%) compared with the post-subsidisation (49.5%, p = 0.008). The negative predictive value of mpMRI for clinically significant PCa was 86.5%. Our institution experienced a reduction of negative prostate biopsies and an increase in clinically significant PCa within transperineal biopsy specimens after the Australian healthcare system introduced financial subsidisation of mpMRI.||URI:||https://ahro.austin.org.au/austinjspui/handle/1/30531||DOI:||10.1002/bco2.140||ORCID:||https://orcid.org/0000-0001-5168-6346
|Journal:||BJUI compass||PubMed URL:||35783586||PubMed URL:||https://pubmed.ncbi.nlm.nih.gov/35783586/||Type:||Journal Article||Subjects:||MRI
|Appears in Collections:||Journal articles|
Show full item record
checked on Nov 28, 2023
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.